Cellectis S.A. (EPA:ALCLS) Stock Catapults 30% Though Its Price And Business Still Lag The Industry
Cellectis S.A. (EPA:ALCLS) shares have had a really impressive month, gaining 30% after a shaky period beforehand. But the gains over the last month weren’t enough to make shareholders whole, as the share price is still down 9.7% in the last twelve months.
In spite of the firm bounce in price, Cellectis may still be sending buy signals at present with its price-to-sales (or “P/S”) ratio of 2.6x, considering almost half of all companies in the Biotechs industry in France have P/S ratios greater than 3.7x and even P/S higher than 16x aren’t out of the ordinary. Nonetheless, we’d need to dig a little deeper to determine if there is a rational basis for the reduced P/S.
